PA-IMMUNOCORE-LIMITED
Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company focused on delivering first-in-class biological therapies that have the potential to transform lives of people with serious diseases, today names David Berman as its new Head of Research and Development.
David joined Immunocore in September 2018 to advance the Company’s lead candidate, IMCgp100, towards commercialisation and progress Immunocore’s growing pipeline of TCR candidates through clinical development.
Over his career, David has worked on immuno-oncology programmes at all stages of development including leadership roles in developing four approved biologics. Most recently, David was Senior Vice President and Head of the AstraZeneca Immuno-oncology (IO) Franchise, where he was responsible for the strategy and execution of the company’s late stage I-O programme. Prior to that, he was head of the early stage oncology programme at MedImmune. David has also held senior development roles at Bristol-Myers Squibb including Head of the Immuno-oncology exploratory development team and global clinical lead for the first approved IO checkpoint inhibitor and one of the first monoclonal antibodies approved for myeloma.
In addition to the development of CTLA4 and PD1/L1 checkpoint inhibitors, David’s experience includes developing a wide range of novel IO targets and combinations as well as translational medicine focused on their mechanisms of action.
David completed his MD at the University of Texas Southwestern Medical School and his PhD in the Laboratory of Dr. Alfred G. Gilman, the 1994 Nobel laureate for his discovery of G-proteins. He completed a residency in Anatomic Pathology at the National Cancer Institute and a Fellowship at The Johns Hopkins University School of Medicine.
Commenting on David’s appointment, Bahija Jallal, Chief Executive Officer of Immunocore, said: “David has a unique pedigree in Immuno-oncology and is ideally qualified to drive our R&D operations at the exciting and important time in our development. His appointment as Head of R&D strengthens Immunocore's leadership team and supports us as we advance our growing pipeline of TCR candidates through clinical development and our lead candidate, IMCgp100, towards commercialisation. My immediate priority for Immunocore is to continue to strengthen the management team with the right scientific and leadership expertise to move the organisation forward. Our science and strategy continues to be one of the most compelling in our industry, in my view, and 2019 will be another important year for the Company.”
“At the heart of cancer immunity is a T cell recognising a cancer antigen and Immunocore has led the way in converting this into a therapeutic,” added David Berman. “By unlocking the T cell receptor with its leading technology platform, Immunocore’s technology has the potential to bring the benefits of IO to those patients and tumours who do not respond to current therapies. I am excited and honoured to be charged with driving Immunocore’s research and development efforts forward.”
- Ends -
About Immunocore
Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. The Company’s primary therapeutic focus is oncology and it also has programs in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programs in development and the lead program, IMCgp100, has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with an office outside Philadelphia, USA. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190114005836/en/
Contact:
Immunocore Zoë Roberts, Communications Manager T: +44 (0)1235 438600 E: info@immunocore.com Follow on Twitter: @Immunocore Consilium Strategic Communications (corporate and financial) Mary-Jane Elliott/Jessica Hodgson/Chris Welsh T: +44 (0)203 709 5700 E: Immunocore@consilium-comms.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 22:32:00 CEST | Press release
Successful Transaction Marks Another Milestone in A-CAP’s Soccer Club Portfolio Strategy Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management
Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 20:00:00 CEST | Press release
Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon
Vertex Presents New Data on Benefits of ALYFTREK® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 18:00:00 CEST | Press release
- Oral presentation on outcomes following treatment with CFTR modulators show that improvements in CFTR function, as measured by lower sweat chloride, correlate with better outcomes for people with cystic fibrosis - - Oral presentation on new post hoc data from randomized, controlled and open-label trials suggest improved quality of life results with ALYFTREK compared to TRIKAFTA® – Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conferenc
Andersen Consulting tilføjer dimension med David and Golyat6.6.2025 16:33:00 CEST | Pressemeddelelse
Andersen Consulting udbygger sin globale konsulentkapacitet gennem en samarbejdsaftale med David and Golyat, en filippinsk konsulentvirksomhed inden for digital strategi. Med et stærkt fokus på business intelligence, kundeindsigt og digital first-eksekvering arbejder David and Golyat med kunder på tværs af flere sektorer – herunder regeringer, udviklingsorganisationer og private virksomheder – for at skabe langsigtet værdi gennem datainformerede beslutninger. Miko David, administrerende partner i David and Golyat, siger: "Vi ser frem til samarbejdet med Andersen Consulting, da det er en milepæl i vores vækstforløb. Ved at kombinere vores ekspertise inden for digital strategi og Andersen Consultings globale platform er vi i stand til at levere endnu større værdi til kunder, der navigerer på komplekse markeder." "Dette samarbejde betyder, at vi kan tilføre en ekstra dimension til vores globale konsulentplatform," siger Mark L. Vorsatz, global bestyrelsesformand og administrerende direktø
IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10th Anniversary Year of NAHYCO® Technology6.6.2025 16:00:00 CEST | Press release
IBSA Derma, the dermoaesthetic division of Swiss company IBSA, will participate in the 18th IMCAS Asia Congress in Bangkok, gathering over 3,000 professionals from across the region to explore the future of aesthetic and regenerative medicine.With the presence in the Congress and a dedicated scientific symposium, the company reaffirms its commitment to advancing bioremodeling approaches and promoting a holistic, science-driven vision of authentic beauty.This year marks a key milestone for IBSA Derma: 10 years of NAHYCO® Technology, a patented innovation in hyaluronic acid science that continues to shape the future of tissue regeneration. IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom